This activity is a case-based discussion with a panel of experts in the field of GU malignancies discussing how to personalize treatment recommendations based on imaging (including MRI, Fluciclovine F18 and Ga68-PSMA scans), pathology and clinical findings for patients with oligometastatic diseas

Patient fertility and sexual complications have few data available from clinical trials. It is noteworthy that the subject is infrequently discussed in institutional peer reviews/ M&M unless there is a Risk Management overlay.

Radiation therapy-induced erectile dysfunction (RI-ED) occurs in over 50% of men treated for prostate cancer. The etiologies are likely multifactorial, consisting of a neurological, vascular and endocrine component.

Conventionally fractionated external beam radiation therapy (EBRT) has a long-standing track record of safety and excellent treatment outcomes in the management of all prostate cancer risk groups.

Molecular diagnostics are rapidly evolving, leading to increased identification of previously 'rare' clinical entities.

Unfavorable intermediate-risk prostate cancer is commonly encountered in clinical practice but there is relatively little data focusing on treatment outcomes specific and limited to this patient cohort, with most clinical trials grouping these patients with favorable intermediate-risk disease or